Investigating how DNA changes affect multiple sclerosis development
DNA methylation in the development of multiple sclerosis
This study is looking at how changes in DNA might affect the risk and progression of multiple sclerosis (MS) by analyzing blood samples from MS patients, with the goal of finding better ways to treat the disease, especially with certain therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11078752 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of DNA methylation in the risk and progression of multiple sclerosis (MS). It involves analyzing blood samples from patients diagnosed with MS to identify specific genetic and epigenetic changes that may influence treatment responses, particularly to anti-CD20 antibody therapies. The study employs advanced techniques to assess gene expression and chromatin accessibility at the single-cell level, aiming to uncover the underlying mechanisms of MS. By integrating various data types, the research seeks to provide insights into the disease's pathogenesis and potential therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals recently diagnosed with multiple sclerosis who have not yet received treatment.
Not a fit: Patients with advanced multiple sclerosis or those who have already undergone extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for multiple sclerosis patients by identifying specific biomarkers that predict treatment response.
How similar studies have performed: Previous research has shown promising results in understanding the genetic and epigenetic factors in multiple sclerosis, suggesting that this approach could yield valuable insights.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Oksenberg, Jorge R. — University of California, San Francisco
- Study coordinator: Oksenberg, Jorge R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.